TY - JOUR
T1 - STereotactic Arrhythmia Radioablation (STAR)
T2 - the Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary consortium (STOPSTORM.eu) and review of current patterns of STAR practice in Europe
AU - Grehn, Melanie
AU - Mandija, Stefano
AU - Miszczyk, Marcin
AU - Krug, David
AU - Tomasik, Bartłomiej
AU - Stickney, Kristine E.
AU - Alcantara, Pino
AU - Alongi, Filippo
AU - Anselmino, Matteo
AU - Aranda, Ricardo Salgado
AU - Balgobind, Brian V.
AU - Boda-Heggemann, Judit
AU - Boldt, Leif Hendrik
AU - Bottoni, Nicola
AU - Cvek, Jakub
AU - Elicin, Olgun
AU - De Ferrari, Gaetano Maria
AU - Hassink, Rutger J.
AU - Hazelaar, Colien
AU - Hindricks, Gerhard
AU - Hurkmans, Coen
AU - Iotti, Cinzia
AU - Jadczyk, Tomasz
AU - Jiravsky, Otakar
AU - Jumeau, Raphaël
AU - Kristiansen, Steen Buus
AU - Levis, Mario
AU - López, Manuel Algara
AU - Martí-Almor, Julio
AU - Mehrhof, Felix
AU - Møller, Ditte Sloth
AU - Molon, Giulio
AU - Ouss, Alexandre
AU - Peichl, Petr
AU - Plasek, Jiri
AU - Postema, Pieter G.
AU - Quesada, Aurelio
AU - Reichlin, Tobias
AU - Rordorf, Roberto
AU - Rudic, Boris
AU - Saguner, Ardan M.
AU - ter Bekke, Rachel M.A.
AU - López Torrecilla, José
AU - Troost, Esther G.C.
AU - Vitolo, Viviana
AU - Andratschke, Nicolaus
AU - Zeppenfeld, Katja
AU - Blamek, Slawomir
AU - Fast, Martin
AU - de Panfilis, Ludovica
AU - Blanck, Oliver
AU - Pruvot, Etienne
AU - Verhoeff, Joost J.C.
N1 - Funding Information: The authors would like to thank all members of the STOPSTORM consortium (see https://stopstorm.eu/en/consortium). Special thanks to Marcus Both and the advisory board members Matthew Bates, Matthew Hatton, Phillip Cuculich, Clifford Robinson, Paul C. Zei, Jan Smook, Reinier Versluis, Annette Rogge, Rieke van der Graaf, Dick Enge, Juan Carlos Miembro, Stephanie Hellwig, and Denis Janssen. The following STOPSTORM participants were part of the Delphi consensus37: David Krug, Oliver Blanck, Nicolaus Andratschke, Raphael Jumeau, Felix Mehrhof, Judit Boda-Heggemann, Etienne Pruvot, Ardan M. Saguner, Boris Rudic, and Leif-Hendrik Boldt. This project has received funding from the European Union's Horizon 2020 research and innovation programme under grant agreement No. 945119. Publisher Copyright: © The Author(s) 2023. Published by Oxford University Press on behalf of the European Society of Cardiology.
PY - 2023/4/1
Y1 - 2023/4/1
N2 - The EU Horizon 2020 Framework-funded Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary (STOPSTORM) consortium has been established as a large research network for investigating STereotactic Arrhythmia Radioablation (STAR) for ventricular tachycardia (VT). The aim is to provide a pooled treatment database to evaluate patterns of practice and outcomes of STAR and finally to harmonize STAR within Europe. The consortium comprises 31 clinical and research institutions. The project is divided into nine work packages (WPs): (i) observational cohort; (ii) standardization and harmonization of target delineation; (iii) harmonized prospective cohort; (iv) quality assurance (QA); (v) analysis and evaluation; (vi, ix) ethics and regulations; and (vii, viii) project coordination and dissemination. To provide a review of current clinical STAR practice in Europe, a comprehensive questionnaire was performed at project start. The STOPSTORM Institutions' experience in VT catheter ablation (83% ≥ 20 ann.) and stereotactic body radiotherapy (59% > 200 ann.) was adequate, and 84 STAR treatments were performed until project launch, while 8/22 centres already recruited VT patients in national clinical trials. The majority currently base their target definition on mapping during VT (96%) and/or pace mapping (75%), reduced voltage areas (63%), or late ventricular potentials (75%) during sinus rhythm. The majority currently apply a single-fraction dose of 25 Gy while planning techniques and dose prescription methods vary greatly. The current clinical STAR practice in the STOPSTORM consortium highlights potential areas of optimization and harmonization for substrate mapping, target delineation, motion management, dosimetry, and QA, which will be addressed in the various WPs.
AB - The EU Horizon 2020 Framework-funded Standardized Treatment and Outcome Platform for Stereotactic Therapy Of Re-entrant tachycardia by a Multidisciplinary (STOPSTORM) consortium has been established as a large research network for investigating STereotactic Arrhythmia Radioablation (STAR) for ventricular tachycardia (VT). The aim is to provide a pooled treatment database to evaluate patterns of practice and outcomes of STAR and finally to harmonize STAR within Europe. The consortium comprises 31 clinical and research institutions. The project is divided into nine work packages (WPs): (i) observational cohort; (ii) standardization and harmonization of target delineation; (iii) harmonized prospective cohort; (iv) quality assurance (QA); (v) analysis and evaluation; (vi, ix) ethics and regulations; and (vii, viii) project coordination and dissemination. To provide a review of current clinical STAR practice in Europe, a comprehensive questionnaire was performed at project start. The STOPSTORM Institutions' experience in VT catheter ablation (83% ≥ 20 ann.) and stereotactic body radiotherapy (59% > 200 ann.) was adequate, and 84 STAR treatments were performed until project launch, while 8/22 centres already recruited VT patients in national clinical trials. The majority currently base their target definition on mapping during VT (96%) and/or pace mapping (75%), reduced voltage areas (63%), or late ventricular potentials (75%) during sinus rhythm. The majority currently apply a single-fraction dose of 25 Gy while planning techniques and dose prescription methods vary greatly. The current clinical STAR practice in the STOPSTORM consortium highlights potential areas of optimization and harmonization for substrate mapping, target delineation, motion management, dosimetry, and QA, which will be addressed in the various WPs.
KW - Cardiac arrhythmias
KW - Consortium
KW - EU Horizon 2020
KW - Stereotactic arrhythmia radioablation
KW - Stereotactic body radiotherapy
KW - Ventricular tachycardia
UR - http://www.scopus.com/inward/record.url?scp=85147553830&partnerID=8YFLogxK
U2 - https://doi.org/10.1093/europace/euac238
DO - https://doi.org/10.1093/europace/euac238
M3 - Review article
C2 - 36879464
SN - 1099-5129
VL - 25
SP - 1284
EP - 1295
JO - Europace
JF - Europace
IS - 4
ER -